The CPHI & PMEC China event held in June 2025 saw a significant rise in international attendance, marking a 30% increase year-on-year. This surge primarily reflects the escalating interest from Western pharmaceutical companies in China-based biotech collaborations, which are driving innovation across global pipelines and fostering increased partnerships within China. Notably, international executives constituted almost a quarter of all attendees, with over 15,000 individuals from abroad participating, indicating substantial growth particularly from Europe and the United States. This event, recognized as Asia’s largest pharmaceutical gathering, welcomed a total of 109,056 attendees from 147 countries, along with 3,600 exhibitors spread across an expansive 240,000+ square meters, solidifying its status as the most significant and globally influential pharma event in the region.
Despite persistent tariff disputes, China’s biopharmaceutical sector has maintained a rapid pace of innovation, partially compensating for the reduced investment and valuations in Western markets. Recent data from Jefferies reveals that China accounted for 32% of all major in-licensing agreements with prominent pharmaceutical companies in the first quarter of 2025, showcasing a notable increase from previous years. With well-funded biotech companies in China driving the development of novel therapies, the country has emerged as a pivotal source of innovation for global pharmaceutical pipelines, particularly in areas such as oncology, autoimmune diseases, and rare conditions. Natasha Jennings, the head of global growth marketing at Informa Markets, highlighted the escalating participation of senior executives from global pharma firms at CPHI China, emphasizing the importance of face-to-face meetings to foster collaborations.
CPHI & PMEC China 2025 featured 14 product zones encompassing the entire pharmaceutical supply chain, ranging from ingredients and CDMO services to finished dosage forms, biologics, machinery, and packaging. The event also witnessed robust engagement in the Bioengineering and Life Sciences zones, attracting significant international interest. The extensive content program included over 90 conferences with 600 expert speakers, with a strong emphasis on topics such as cross-border licensing, regulatory partnerships, AI-driven research and development, and strategies for technology transfer. As the industry gears up for the upcoming CPHI & PMEC Shenzhen event scheduled for September 2025, set in the vibrant Greater Bay Area, the focus shifts to a region known for its pharmaceutical innovation and manufacturing capabilities, offering a ‘five-day visa free’ environment for international attendees, which is a unique advantage.
Anticipating 10,000 visitors at the CPHI & PMEC Shenzhen event, including an increasing number of Western pharma companies and dealmakers, the gathering promises a conducive setting for connecting with Chinese biotech firms ready for licensing agreements in one of the world’s most innovation-rich regions. Shenzhen, being a prominent hub for biotech innovation and manufacturing in China, particularly in early and mid-clinical stages, presents an ideal landscape for business development opportunities. The event in Shenzhen is poised to provide Western pharmaceutical companies with direct access to the heart of China’s dynamic biotech ecosystem and promising assets, fostering further international collaboration and innovation exchange.
Key Takeaways:
– The CPHI & PMEC China 2025 event witnessed a substantial increase in international attendance, showcasing growing interest from Western pharmaceutical companies in collaborations with China-based biotechs.
– China’s biopharmaceutical sector is rapidly innovating, with a significant share of in-licensing deals with major pharma companies originating from the country, highlighting its emerging role in driving global pharmaceutical innovation.
– The upcoming CPHI & PMEC Shenzhen event presents a strategic platform for Western pharma firms to engage with Chinese biotech innovators in a region renowned for its biotech advancements and manufacturing capabilities, fostering cross-border partnerships and technology transfer.
Tags: tech transfer, biotech, biopharma, regulatory, pharmaceutical manufacturing
Read more on pharmabiz.com